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During the past decade considerable interest
has focused on markers of inflammation in general,
and C-reactive protein (CRP) specifically, in an at-
tempt to improve cardiovascular risk prediction.
Multiple prospective epidemiological studies have
shown an association between increased levels of
inflammatory markers and the risk of incident myo-
cardial infarction (MI), stroke, peripheral arterial
disease, and sudden cardiac death [1–5]. These data
were supported by laboratory and experimental
evidence that have demonstrated that atherothrom-
bosis, in addition to being a disease of lipid accu-
mulation, also represents a chronic inflammatory
process [6, 7]. Despite this, however, a recent re-
port from the Framingham Heart Study has shown
that for assessing risk in individual persons the use
of the multiple contemporary biomarkers adds only
moderately to standard risk factors for the predic-
tion of cardiovascular risk [8]. Thus, in outpatient
settings, the primary use of CRP has been recom-
mended as an adjunct for cardiovascular risk assess-
ment mainly in patients at intermediate risk, as
defined by the Framingham Risk Score [9].
In post-MI patients the role and potential util-
ity of inflammatory risk markers is even less cer-
tain. This may possibly be due to the fact that in
the contemporary era of aggressive coronary revas-
cularization and management with lipid lowering
therapies in this population, it is more difficult to
identify the incremental prognostic yield of inflam-
matory markers. Furthermore, in the post-MI
period there are multiple potential stimuli for pro-
duction of markers of inflammation that may mask
the relatively minor increases in the levels of these
markers that occur as a result of vascular inflam-
mation. Inflammatory markers have been investi-
gated in a secondary setting in several studies, and
have been shown to predict risk of both recurrent
ischemia and death among patients with acute cor-
onary syndromes [10, 11], and among those in the
chronic phase after acute MI [12–14]. However, in
all prior analyses, markers of inflammation were
univariate predictors of risk, and the impact of these
markers was reduced when adjustment was made
for the presence of important confounding factors
that have a closer association with outcome in the
postinfarction period. In a report by Lindahl et al. [10],
CRP measurements during the acute MI phase
were associated with long-term mortality, but no
adjustment was made for left ventricular dysfunc-
tion. Similarly, Tommasi et al. [13] reported that
increased CRP levels obtained during the acute MI
phase correlate with subsequent outcome, despite
the fact that CRP levels may correlate with infarct
size in the early post-MI period.
The association of inflammatory markers,
including CRP and serum amyloid A (SAA), with
recurrent coronary events was assessed in the pro-
spective multicenter THROMBOgenic risk-factor
(THROMBO) study that was initiated in our insti-
tute [14]. The study enrolled 1045 stable postinf-
arction patients in whom lipid, hemostatic and in-
flammatory factors were measured 2 months after
the index MI. All patients were assessed for recur-
rent cardiac events during a subsequent 2-year fol-
low-up period. Consistent with prior studies of in-
flammatory markers in a secondary prevention
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setting, unadjusted Cox analysis in THROMBO re-
vealed an increasing risk of recurrent coronary
events with increasing quartile levels of CRP and
SAA. However, after multivariate adjustment, none
of the analyzed inflammatory markers was identi-
fied as a significant predictor for recurrent coronary
events during the 2-year follow-up period.
In this issue of the journal, Marcinkowski et al. [15]
provide an interesting, and potentially important,
contribution to the controversial field of the role of
inflammatory markers as predictors of risk in a sec-
ondary setting. The study was carried out in
107 patients with a first MI who were followed up
for 18 months. Similar to THROMBO, the end point
of this study comprised of cardiac death, nonfatal
reinfarction or unstable angina pectoris. However,
there are several important differences between
this study and THROMBO that might have led to
different findings. First, despite a relatively small
sample size, 90% of the patients in the study by
Marcinkowski et al. [15] experienced ST-elevation
MI, making this study cohort a higher-risk popula-
tion than in THROMBO, with a higher event rate
during follow-up. This may have facilitated a com-
prehensive analysis of the association between in-
flammatory markers and recurrent coronary events.
Second, while serum levels of CRP and SAA were
assessed in THROMBO only at the 2-month follow-
up visit, Marcinkowski et al. [15] employed a more
dynamic risk-assessment, in which serum levels of
several inflammatory markers (including CRP,
fibrinogen, soluble intercellular adhesion molecule 1,
erythrocyte sedimentation rate, and white blood cell
count) were obtained at 2 time-points after the in-
dex MI — at an early phase (10 days) and at a later
post-recovery phase (10 weeks). The study dem-
onstrates that obtaining levels of inflammatory
markers close to the acute postinfarction phase does
not contribute significantly to risk prediction, pos-
sibly due to the fact that increased levels of these
biomarkers during the acute phase are closely re-
lated to infarct size and tissue injury, whereas
among patients in whom inflammatory markers re-
main elevated from day 10 through week 10 there
is a significant increase in the risk of recurrent cor-
onary events. These findings further stress the
importance of dynamic risk-assessment in post-MI
patients. Repeated measures facilitate assessment
of time-dependent changes in markers of coronary
risk. Thus, early changes in levels of inflammatory
markers are probably more closely associated with
the index event than with subsequent risk, where-
as long-term changes in the levels of these mark-
ers may be more closely associated with outcome.
Most randomized trials today evaluate variables that
are obtained during enrollment or the index event
and do not take into account effect of long-term
changes in risk factors. The findings of
Marcinkowski et al. [15] suggest that continuous
risk-assessment of the quantitative changes in risk
markers over time yields the possibility of greater
positive or negative predictive accuracy of event
rates. It is possible that longer-term follow-up of
changes in levels of inflammatory markers in this
population will further improve dynamic risk-as-
sessment of outcome and response to therapy. This,
possibility, however, needs to be evaluated in fu-
ture studies.
Despite the interesting findings by Marcinkowski
et al. [15] several important limitations of this study
should be mentioned. Of the 22 patients who expe-
rienced the study’s composite end point, the over-
whelming majority (16 patients; 72%) had unstable
angina, whereas more severe end points such as
cardiac death and reinfarction occurred in only one
and five patients, respectively. Thus, it is possible
that the association between levels of inflammatory
markers at 10 weeks and recurrent events is signifi-
cant only when the end point of recurrent ischemia is
assessed. Future studies, with a larger sample size
and a longer-term follow-up period, are needed to
validate if the findings persist after adjustment for
“classic” risk factors such as age and infarct size when
more severe end points (e.g. cardiac death, reinfarc-
tion, or heart failure events) are assessed. It should
also be noted that study patients had variable follow-up
periods, and that end point events occurred at differ-
ent time-points. Thus, the usage of logistic regres-
sion analysis may not be applicable when censored
data are analyzed. Importantly, Marcinkowski et al. [15]
were careful to validate the consistency of their re-
sults using Cox analysis, which is a more suitable sta-
tistical methodology for this study.
The results of the study by Marcinkowski et al. [15]
provide supportive evidence that evaluation of in-
flammatory markers relatively late in the postinf-
arction period may be important for long-term risk-
stratification, and stress the importance of contin-
uous profiling and risk-assessment in postinfarction
patients. These findings should be incorporated in
the design of future trials that evaluate the role of
inflammatory markers as predictors of outcome in
post MI patients.
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